-
Recent Posts
- Dementia-Friendly Communities Provision, Viewed as a Social Determinant of Health (JGCR / NHS England / WHO)
- International Perspectives on the Possible Impact of the COVID-19 Pandemic and Lockdown on Abuse of the Elderly (JGCR / American Journal of Geriatric Psychiatry / JAGS)
- Updates Relating to the Lancet Commission on Dementia Prevention, Intervention, and Care (Lancet / Alzheimer’s Research and Therapy / Alzheimer’s and Dementia)
- A Brief Review of How the COVID-19 Pandemic Relates to Elderly Care and Research (JGCR)
- Some Speculated / Potential Benefits of COVID-19 (JGCR / BBC Radio 4’s Rethink / BGS)
Archives
- September 2020
- August 2020
- June 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Department of Health and Social Care (DHSC)
- Health Education England (HEE)
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Employers
- NHS England
- NHS Evidence
- NHS Improvement
- NICE Guidelines
- NIHR
- NIHRSDO
- Northern Ireland
- Patients Association
- Public Health England
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Wales
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Google Translate (100+ Languages)
Tag Archives: Pharmaceutical Industry
A Further Set-Back for Progress in Dementia Drug Development? (BBC News)
Summary Drug company Pfizer is to cease activity in its neuroscience drug discovery programmes, which will impact on ongoing research into drugs for Alzheimer’s Disease and Parkinson’s Disease. Paradoxically the company does promise plans to create a new fund dedicated … Continue reading →
Posted in BBC News, For Researchers (mostly), In the News, International, Management of Condition, Pharmacological Treatments, Quick Insights, Universal Interest
|
Tagged Big Pharma, Dementia Research, Dementia Research Funding, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Discovery Programmes, Drug Identification, Drug Trials Failure Rate, Drug-Development Pipeline, Global Context, Global Outlook, International Organisations, International Programmes, Neurological Conditions, Neurological Disease, Neurological Disorders, Neuroscience Drug Discovery Programmes (Pfizer), Neuroscience Research, Pfizer, Pfizer Inc., Pharmaceutical Industry, Research and Development, Research and Innovation, Research Commitment, Research Funding
|
Leave a comment
New Cancer Drugs Often Bestow Little Benefit Regarding Survival or Wellbeing? (NHS Choices / BMJ)
Summary A quotation from the authors’ abstract may say it all: “This systematic evaluation of oncology approvals by the European Medicines Agency (EMA) in 2009-13 shows that most drugs entered the market without evidence of benefit on survival or quality … Continue reading →
Posted in Commissioning, For Doctors (mostly), For Nurses and Therapists (mostly), For Social Workers (mostly), In the News, International, Management of Condition, NHS Digital (Previously NHS Choices), Pharmacological Treatments, Quick Insights, Statistics, Systematic Reviews, UK, Universal Interest
|
Tagged Advanced Melanoma: Improving Survival Rates, Assessment of Quality of Life, Bazian, Behind the Headlines, Better Regulation, Big Pharma, BMJ Publishing Group Ltd, British Medical Journal (BMJ), Cancer, Cancer Drugs Approved by EMA (2009-13), Cancer Drugs Approved on Basis of Surrogate End Points, Cancer Drugs Fund (CDF), Cancer Pharmaceuticals (New Approvals), Cancer Research, Cancer Survival, Cancer Survival Group: London School of Hygiene and Tropical Medicine, Cancer Treatment (Newer Drugs), Combination Nivolumab Plus Ipilimumab, Department of Global Health and Social Medicine: King's College London, Department of Health Policy: London School of Economics and Political Science, Department of Health Services Research and Policy: London School of Hygiene and Tropical Medicine, Drug Regulation, EMA: European Medicines Agency, European Medicines Agency, European Medicines Agency (Cancer Drug Approvals), European Medicines Agency (EMA), European Public Assessment Reports (EPARs), European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS), European Society for Medical Oncology's Magnitude of Clinical Benefit Scale (MCBS), Evidence Versus Mythology, Faculty of Pharmacy: Riga Stradins University, Institute of Cancer Policy: King's College London, Kings College London, Latvia, London, London School of Economics and Political Science, London School of Hygiene and Tropical Medicine, London School of Hygiene and Tropical Medicine (LSHTM), LSE Health: London School of Economics and Political Science, LSHTM: London School of Hygiene and Tropical Medicine, Market Approval (New Cancer Drugs), Myth-Busting, Myths and Misconceptions About New Cancer Drugs, New Cancer Drug Approvals (EMA), Pharmaceutical Industry, Pharmaceutical Regulators, Pharmaceuticals, Quality of Life, Regulatory Experts, Regulatory Requirements, Regulatory Stringency, Regulatory System, Riga Stradins University (Latvia), Skin Cancer, Surrogate End Points Versus Subsequent Efficacy / Survival, Thinking Like a Patient and Acting Like a Taxpayer
|
Leave a comment
New Drugs for Dementia (POST Note PN 535)
Summary The Parliamentary Office of Science and Technology (POST) has produced a briefing outlining some of the challenges in developing new drugs for dementia, explained in the context of ongoing UK and international research programmes. There is an extensive bibliography, … Continue reading →
Posted in Alzheimer's Society, Alzheimer’s Research UK, Antipsychotics, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Models of Dementia Care, National, Pharmacological Treatments, Quick Insights, Statistics, UK, Universal Interest
|
Tagged Academic Institutes in the UK, Academy of Social Sciences, Aducanumab (Biogen), Alzheimer’s Association, Alzheimer’s Research UK’s Drug Discovery Alliance, Behavioural and Psychological Symptoms of Dementia (BPSD), Big Data, Big Data Funding and Research, Big Pharma, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, BPSD: Behavioral and Psychological Symptoms of Dementia, British Psychological Society (BPS), Co-ordination and Data Analytics, Cognitive Health in Ageing Register for Investigations, Collaborative Projects, Collaborative Research, Dementia Consortium, Dementia Risk Prevention, Dementias Platform UK, Dementias Platform UK (DPUK), Dementias Platform UK: MRC, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), DPUK: Dementias Platform UK, Drug Discovery Alliance, Drug Licensing Approval, Drugs for BPSD, Drugs for Cognitive Symptoms of Cognitive Decline and Dementia, EAMS: Early Access to Medicines Scheme, Early Access to Medicines Scheme, Effective Non-Drug Interventions, Etanercept, European Prevention of Alzheimer's Dementia Consortium (EPAD), European Prevention of Alzheimer’s Dementia Consortium, Identification of People At Risk of Dementia, International Collaborations, International Programmes, International Research, Join Dementia Research, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, New Drugs for Dementia (POST Note PN 535), NIHR Clinical Research Network, Observations & Trials in Dementia Research, Parliament, Parliamentary Office of Science & Technology, Parliamentary Office of Science & Technology (POST), Participation in Research, Patient Access to New Drugs, Pharmaceutical Industry, Pioglitazone, POST: Parliamentary Office of Science & Technology, Pre-Symptomatic Diagnosis of Dementia, Preclinical Biomarkers and Dementia, Preclinical Indicators and Dementia, Prevention, Public Participation in Research, Research and Development, Research and Innovation, Research Commitment, Research Culture, Research Mapping, Research Networks, Solanezumab (Eli Lilly), Symptom-Modifying Drugs for Dementia, UK Dementia Research Institute, UK Parliament, UK Patient Recruitment Initiatives, Verubecestat (Merck), Well-Being and Health for People With Dementia (WHELD) Program
|
Leave a comment
European Medicines Agency Consultation on Pharmacological Treatments for Dementia (EMA)
Summary The European Medicines Agency (EMA) has released an updated draft guideline on medicines for the treatment of Alzheimer’s Disease and other types of dementia, for consultative feedback. Full Text Link Reference Consultation on revised guideline on medicines to treat … Continue reading →
Posted in Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Management of Condition, Mental Health, Models of Dementia Care, Pharmacological Treatments, Quick Insights, Standards
|
Tagged Accelerating Alzheimer's Research and Drug Development, Alzheimer’s Disease Biomarkers, Behavioural and Psychiatric Symptoms of Dementia, Behavioural and Psychological Symptoms of Dementia (BPSD), Biomarker Assessments in Alzheimer’s Disease, Biomarker Assessments in Alzheimer’s Disease Clinical Trials, Biomarker Assessments in Clinical Trials, Biomarker Development, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Blood Proteins as Biomarkers of Disease Research, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer’s Disease, BPSD: Behavioral and Psychological Symptoms of Dementia, Cardiovascular Adverse Events, Clinical Diagnostic Criteria, Committee for Medicinal Products for Human Use (CHMP), Comparison IWG and NIA-AA Criteria for Clinical Diagnosis of Alzheimer´s Disease, Diagnostic Tests, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Development for Alzheimer's Disease, Drug Discovery Programmes, Drug Identification, Drug Target Validation, Drug-Development Pipeline, Drugs for Treatment of Alzheimer’s Disease, Early Detection of Preclinical Disease, Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Early Diagnostic Criteria, EMA Central Nervous System Working Party, EMA: European Medicines Agency, Enrichment of Study Populations, European Medicines Agency, European Medicines Agency (EMA), Genetic Testing, Genetic Triggers, Genetics of Alzheimer's Disease, Guideline on Clinical Investigation of Medicines for Alzheimer’s Disease and Other Dementias, Guideline on Medicinal Products for the Treatment of Alzheimer’s Disease and Nine Other Dementias, International Organisations, International Programmes, International Working Group (IWG), Long-Term Efficacy and Safety Studies, Medical Research, Medicines Development, Medicines Mechanism of Action, National Institutes of Health (NIH), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurological Adverse Events, Neurological Disorders, Novel Targets in Neurodegeneration, Ordering of Alzheimer's Disease Biomarkers, Pharmaceutical Industry, Pharmacological Research, Preclinical Alzheimer's Disease, Preclinical Biomarkers in Alzheimer's Disease, Preclinical Indicators and Dementia, Preclinical Indicators in Alzheimer's Disease, Prodromal Alzheimer's Disease, Psychiatric Adverse Events, Research and Development, Research and Innovation, Research Commitment, Research Consortia, Research Culture, Research Networks, Research Programmes, Safety and Efficacy Markers, Stratification of Subgroups (Clinical Trials), Target Discovery and Preclinical Validation, Therapeutic Target(s): Identification, Timely Diagnosis
|
Leave a comment
Dementia Discovery Fund Launched (WDC / ARUK)
Summary The Dementia Discovery Fund (DDF) was launched on October 21st 2015. Full Text Link Reference Launch of Dementia Discovery Fund. London [Online]: World Dementia Council (WDC), November 10th 2015. See also: Full Text Link Reference $100m Dementia Discovery Fund … Continue reading →
Posted in Alzheimer’s Research UK, Charitable Bodies, Commissioning, Department of Health, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Mental Health, Models of Dementia Care, National, Pharmacological Treatments, Quick Insights, UK, Universal Interest
|
Tagged $100m Dementia Discovery Fund, Ageing and Dementia, Ageing and Society, Ageing Population, Alzheimer's Research UK, Alzheimer’s Research UK (ARUK), Andrew Plump: Chief Medical and Scientific Officer at Takeda Pharmaceutical Company Limited, ARUK: Alzheimer’s Research UK, Big Pharma, Biogen, Biopharmaceutical Companies, Collaboration, Collaborative Projects, Cross-Sector Partnerships, Dementia Discovery Fund, Dementia Discovery Fund (DDF), Dementia Research, Dementia Research Funding, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dr Jan Lundberg: President of Lilly Research Laboratories, Dr Matthew Norton: Alzheimer's Research UK, Drug Discovery Programmes, Drug Identification, Drug Regulation, Drug-Development Pipeline, Eli Lilly Inc., Eli Lilly’s UK Dementia Research Centre, First Global Ministerial Conference on Global Action Against Dementia, First WHO Ministerial Conference on Global Action Against Dementia, G8 Dementia Summit: Global Action Against Dementia, GlaxoSmithKline, Global Action Against Dementia, Global Action Against Dementia (GAAD), Global Ministerial Conference on Global Action Against Dementia (WHO), Global Outlook, Government Research Funding, GSK Johnson & Johnson, International Collaborations, International Programmes, Jane Ellison, Johnson & Johnson, Lilly, Mikael Dolsten: President of Worldwide Research and Development at Pfizer, Partnership, Partnership and Collaboration, Partnership Working, Patrick Vallance: President of Pharmaceuticals R&D at GSK, Paul Stoffels: Worldwide Chairman of Johnson & Johnson, Pfizer, Pfizer Inc., Pharmaceutical Industry, Research and Development, Research and Innovation, Research Commitment, Research Funding, SV Life Sciences, SV Life Sciences (SVLS), Takeda, WDC: World Dementia Council, World Dementia Council
|
Leave a comment
Announcements From WHO’s First Ministerial Conference on Global Action Against Dementia Conference (Dementia Challenge / Department of Health / World Dementia Council / WHO / GAAD)
Summary Health Secretary Jeremy Hunt has announced a $100 million Dementia Discovery Fund at the World Health Organisation’s First Ministerial Conference on Global Action Against Dementia Conference. The Dementia Discovery Fund will be used to finance dementia research with the … Continue reading →
Posted in Acute Hospitals, Charitable Bodies, Commissioning, Community Care, Department of Health, Diagnosis, End of Life Care, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), In the News, Integrated Care, International, Management of Condition, Mental Health, Models of Dementia Care, National, NIHR, Non-Pharmacological Treatments, Patient Care Pathway, Person-Centred Care, Pharmacological Treatments, Quick Insights, Standards, Statistics, UK, Universal Interest, World Health Organization (WHO)
|
Tagged $100m Dementia Discovery Fund, Ageing and Dementia, Ageing and Society, Ageing Population, Alzheimer's Research UK, Alzheimer’s Research UK (ARUK), ARUK: Alzheimer’s Research UK, Awareness Raising, Big Pharma, Biogen, Biopharmaceutical Companies, Burden of Dementia, Challenge on Dementia (David Cameron), Collaboration, Collaborative Projects, Cross-Sector Partnerships, Dementia Challenge, Dementia Diagnosis, Dementia Discovery Fund, Dementia Research, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dr Margaret Chan: WHO Director-General, Drug Discovery Programmes, Drug Identification, Drug Regulation, Drug-Development Pipeline, Eli Lilly Inc., Eli Lilly’s UK Dementia Research Centre, First Global Ministerial Conference on Global Action Against Dementia, First WHO Ministerial Conference on Global Action Against Dementia, Former Health Secretary Jeremy Hunt, G8 Dementia Summit: Global Action Against Dementia, GlaxoSmithKline, Global Action Against Dementia, Global Action Against Dementia (GAAD), Global Ministerial Conference on Global Action Against Dementia (WHO), Global Outlook, Government Research Funding, Human Rights, International Collaborations, International Programmes, Johnson & Johnson, JP Morgan, Knowledge Translation, Leadership, Lilly, Ms. Cathrin Petty: JP Morgan, OECD, Organisation for Economic Co-operation and Development (OECD), Organisation for Economic Co-operation and Development (OECD) Countries, Partnership, Partnership and Collaboration, Partnership Working, Pfizer, Pfizer Inc., Pharmaceutical Industry, Prime Minister’s Dementia Challenge, Quality of Care, Quality of Care and Support, Quality of Care for People With Dementia, Reducing Stigma, Research and Development, Research and Innovation, Research Commitment, Research Funding, Rt Hon Jeremy Hunt MP: Former Secretary of State for Health, WDC: World Dementia Council, World Dementia Council, World Health Organisation (WHO)
|
Leave a comment
Big Data Portal for Alzheimer’s Dementia Drug Discovery (NIH / Synapse AMP-AD)
Summary The National Institutes of Health (NIH) in the USA has opened a public-private partnership online resource to facilitate neurodegenerative research and drug development. The launch of the Alzheimer’s Big Data Portal provides an open-source “public knowledge portal” for the … Continue reading →
Posted in Charitable Bodies, For Doctors (mostly), For Researchers (mostly), In the News, International, Pharmacological Treatments, Quick Insights
|
Tagged Academia-Industry Partnerships, Academia-Industry Synergies, Accelerating Alzheimer's Research and Drug Development, Accelerating Medicine Partnership for Alzheimer's Disease (NIA-AMP AD) Target Discovery and Preclinical Validation Project, Accelerating Medicines Partnership (AMP), Accelerating Medicines Partnership-Alzheimer's Disease (AMP-AD), Alfred P. Sloan Foundation, Alzheimer’s Disease Biomarkers, Alzheimer’s Disease Cooperative Study, Alzheimer’s Disease Neuroimaging Initiative (ADNI), AMP-AD Program, Big Data, Big Data Portal for Alzheimer’s Dementia Drug Discovery, Big Pharma, Biomarkers, Biopharmaceutical Companies, Broad Institute of MIT and Harvard, Collaboration, Collaborative Drug Discovery Programmes, Collaborative Projects, Cross-Sector Partnerships, Dementia Research, Drug Development for Alzheimer's Disease, Drug Discovery Programmes, Drug Identification, Drug Target Validation, Drug-Development Pipeline, Drugs for Treatment of Alzheimer’s Disease, Emory University, Foundation for the NIH (FNIH), Genetic Research, Genetic Testing, Genetic Triggers, Genetics of Alzheimer's Disease, Global Open Data Initiative, Human Epigenome Atlas, Icahn School of Medicine at Mount Sinai, Institute for Systems Biology (Seattle), International Alzheimer's Disease Research Portfolio (IADRP), International Collaborations, International Organisations, International Programmes, Market Failure (Dementia Research and Drug Development), Mayo Clinic in Jacksonville, Medical Research, Multidisciplinary Research Teams, National Institutes of Health (NIH), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, NIA Genetics of Alzheimer’s Data Storage Site (NIAGADS), NIH Big Data to Knowledge (BD2K) Initiative, NIH Network for Excellence in Neuroscience Clinical Trials, Non-Profit Collaborations, Novel Targets in Neurodegeneration, Open Data, Open Data and Big Data, Open Data in Health and Social Care, Open Data Learning Capacity and Culture, Open Data: Unlocking Innovation, Open Source Solutions, Pharmaceutical Industry, Pharmacological Research, Potential of Open Data in Health and Social Care, Pre-Competitive Collaboration, Precision Medicine Initiative, Preclinical Biomarkers in Alzheimer's Disease, Public-Private Partnership (PPP), Public-Private Partnerships, Research and Development, Research and Innovation, Research Commitment, Research Consortia, Research Culture, Research Networks, Research Programmes, Roadmap Epigenomics Project, Rush University Medical Center: Chicago, Sage Bionetworks, Synapse, Synapse Access and Compliance Team, Target Discovery and Preclinical Validation, Technology Transfer, Temporal Evolution of Alzheimer’s Disease Biomarkers, Therapeutic Target(s): Identification, Translational Research, Transparency and Open Data, United States, University of California, University of Florida, US National Institute of Aging, US National Institutes of Health (NIH), USA
|
Leave a comment
Prime Minister’s Challenge On Dementia 2020: £300m Government Funding Planned For Dementia Research (BBC News / Department of Health)
Summary In the wake of the three-year Prime Minister’s “Dementia Challenge” (2012), David Cameron has announced the follow-up Prime Minister’s Challenge On Dementia 2020. The plan is to further transform dementia research, dementia care and support. It is anticipated that … Continue reading →
Posted in Acute Hospitals, Alzheimer's Society, Alzheimer’s Research UK, Antipsychotics, BBC News, Charitable Bodies, Commissioning, Community Care, Department of Health, Diagnosis, End of Life Care, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), Health Education England (HEE), In the News, Integrated Care, International, Management of Condition, Mental Health, Models of Dementia Care, National, NHS, NIHR, Non-Pharmacological Treatments, Patient Care Pathway, Patient Information, Person-Centred Care, Personalisation, Pharmacological Treatments, Public Health England, Quick Insights, Standards, Statistics, UK, Universal Interest, World Health Organization (WHO)
|
Tagged 5YFV: NHS Five Year Forward View, Academia-Industry Partnerships, Achieving Dementia Friendly Acute care, Age-Friendly Housing, Ageing and Dementia, Ageing and Society, Ageing Policy in the UK, Ageing Population, Alistair Burns: NHS England’s National Clinical Director for Dementia, Alzheimer's Association, Alzheimer’s Research UK (ARUK), Alzheimer’s Research UK Stem Cell Research Centre, Alzheimer’s Society Connecting Communities Project, Attributable Cost of Dementia, Awareness and Understanding, Awareness Campaigns, Barbara’s Story: Increasing Awareness of Dementia, Behavioural Risk Factors, Behavioural Risk Factors and Dementia, Better Care Fund, Black Asian and Minority Ethnic (BAME), Black Asian and Minority Ethnic Communities (UK), British Prime Minister's Office, Building Dementia Friendly Communities, Burden of Dementia, Butterfly Approach, Butterfly Scheme, Cambridgeshire and Peterborough NHS Foundation Trust (CPFT) NHS Memory Clinic, Care and Compassion, Care at Home, Care Certificate, Carer Support, Carer Support Services, Challenge on Dementia (David Cameron), Citizen Participation, Collaboration, Collaborative Projects, Collaborative Research, Collaborative Working, Commitment to Carers (NHS England), Community Participation, Compassionate Care, Connecting Communities, Connecting Communities Initiative, Core Knowledge and Skills Framework, Crawley, Crawley Forward Thinking, Creating Dementia Friendly Environments, Creating Dementia Friendly Hospitals, Cross-Sector Partnerships, David Cameron, Dementia Action Alliance (DAA), Dementia Advisers, Dementia Advisor, Dementia Advisor Service, Dementia Awareness, Dementia Awareness Training, Dementia Challenge, Dementia Consortium, Dementia Friendly Charters, Dementia Friendly Communities Recognition Process: Crawley, Dementia Friends, Dementia Friends Campaign, Dementia Friends Champions, Dementia Friends Programme, Dementia Health and Care Champion Group, Dementia Research, Dementia Risk Factors, Dementia State of the Nation, Dementia Voice, Dementia-Friendly Businesses, Dementia-Friendly Care Homes, Dementia-Friendly Cities, Dementia-Friendly Communities, Dementia-Friendly Employers, Dementia-Friendly Football Clubs, Dementia-Friendly Hospitals, Dementia-Friendly Housing, Dementia-Friendly Neighbourhoods, Dementia-Friendly Sectors, Dementia-Friendly Towns, Dementias Platform UK, Dementias Platform UK (DPUK), Dennis Gillings: Former World Dementia Envoy, Department of Health Dementia Challenge, Department of Health Dementia Challenge (2020), Dignity in Care, Dignity in Dementia, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, DPUK: Dementias Platform UK, Elderly Human Rights, End of Life Care, End of Life Care for People with Dementia, Engaging Businesses in Dementia Friends, EPAD: European Prevention of Alzheimer's Dementia Consortium, EU Joint Action on Dementia 2015-18, EU Joint Programme on Neurodegenerative Disease Research (JPND), European Joint Action on Dementia: ALCOVE, European Prevention of Alzheimer's Dementia Consortium (EPAD), Finance and Incentives, Five Year Forward View (NHS England), Focused Intervention Training and Support (FITS), Forget Me Not Club, Forget Me Not Initiative, Free Open Access Journals, G8 Dementia Summit: Global Action Against Dementia, GCTF: Global Clinical Trials Fund, Global Action Against Dementia, Global Burden of Dementia, Global Clinical Trials Fund (GCTF), Global Fund on Dementia, Global Leadership, Global Outlook, Global Social Investment for Dementia, Global Societal Economic Cost of Dementia, Gnosall Model for Dementia, Greenwich Advanced Dementia Service (GADS), Greenwich Carers Centre, Guy’s and St Thomas’ NHS Foundation Trust (GSTT), Harrogate and District NHS Foundation Trust, Health and Care of Older People, Health and Housing Memorandum of Understanding (MoU), Healthy Behaviours, Healthy Communities, Healthy Lifestyles, Hilary Evans: Charity Director of Alzheimer’s Research UK, Housing and Dementia, Improving Care for People with Dementia, Inappropriate Prescribing, Inappropriate Use of Antipsychotics in Dementia, Independent Expert for the Human Rights of Older People, Innovation for an Ageing Population, Integrated Development Pathway, Integration of Health and Care, International Collaborations, International Dementia Research Institute, International Dementia Research Inventories, International Programmes, Involvement and Participation, Jewish Care, Join Dementia Research, Join Dementia Research: Recruitment Onto Dementia Studies, Joint Action on Dementia, Joint Programme on Neurodegenerative Disease Research (JPND), Knowledge and Skills Required for Case Management, Leyton Orient: Dementia-Friendly Football Club, Lifestyle Risk Factors, Local Dementia Action Alliances, Local Dementia Action Alliances in England, Local Government, Local Health and Care Economies, Local Health and Care Services, Local Health and Wellbeing Boards, Loneliness and Dementia, Loneliness and Social Isolation, Maintaining Independence, Marks and Spencer, Medical Research Council (MRC), Men in Sheds, Modifiable Risk Factors, National Dementia and Antipsychotic Prescribing Audit 2012, National Institute for Health Research (NIHR), NHS England's Five Year Forward View (2014), NHS England’s Commitment to Carers, NHS Five Year Forward View (5YFV), NHS Health Check, NHS Health Check Programme, NICE Quality Standards, NIHR Dementia Translational Research Collaboration, One Million NHS Staff Trained (Dementia Awareness), Open Access Databases, Open Access Journals, Open Access Knowledge Resources, Open Access Research, Open Science, Open Science and Data, Open Source Solutions, Organisation for Economic Co-operation and Development (OECD), Otto Schiff Care Home (Golders Green), Oxleas NHS Foundation Trust, Participation in Research, Participation in Research Studies, Partnership and Collaboration, Partnership Working, Patient and Public Participation, PETALS (Person-Centred Empowerment Trust Activities Life History and Stimulation), Peterborough City Council, Pharmaceutical Industry, PM Challenge on Dementia: Health and Care Champion Group Subgroup on Dementia and Homecare, Prevalence of Dementia, Prime Minister's Challenge on Dementia, Prime Minister's Office, Prime Minister’s Challenge On Dementia 2020, Prime Minister’s Dementia Challenge, Prof; Simon Lovestone: Co-Lead Academic Scientists at Oxford Drug Discovery Institute, Professor Alistair Burns, Public Health England (PHE), Public Participation in Research, Public Sector, Public Sector Outcomes, Reducing Inappropriate Use of Antipsychotics in Dementia, Reducing Stigma, Referrals, Research and Innovation, Resource and Incentives, Resources for Enhancing Alzheimer's Caregiver Health (REACH), Risk Factors, Risk Factors for Alzheimer's Diseease, Risk Management, Road Less Rocky, Rosa Kornfield-Matte: Independent Expert on Human Rights, Science and Innovation, Skills for Care, Somerset Care, South Manchester Memory Service, START, START: STrAtegies for RelaTives, State of the Nation Report: Dementia Care and Support in England (2013), Staying Independent, Stem Cell Research Centre, Stigma of Dementia, STrAtegies for RelaTives, Support for Carers, Sustainable Care, Sustainable Health and Care Services, Tackling Barriers to Innovation, Triangle of Care for Dementia, Trinity Homecare, UK Black Asian and Minority Ethnic Communities, Unhealthy Behaviours, Unhealthy Lifestyles, Unhealthy Living, World Dementia Council, World Dementia Envoy
|
Leave a comment
Phase III Gantenerumab Trial for Prodromal Alzheimer’s Disease Discontinued (Biospace Inc)
Summary The Scarlet RoAD study (a Phase III trial), researching the anti-amyloid drug Gantenerumab for the possible treatment of prodromal (pre-dementia) Alzheimer’s Disease, has been abandoned following disappointing results. Gantenerumab-related research (in a different Phase III investigation) is still underway … Continue reading →
Posted in For Doctors (mostly), For Researchers (mostly), In the News, International, Pharmacological Treatments, Quick Insights
|
Tagged Amyloid, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Anti-Amyloid Therapies, Antidementia Drugs, Big Pharma, Biospace, Clinical Trials (Phase I Through Phase III), Crenezumab, Drug Trials, Drug Trials Failure Rate, Drug-Development Pipeline, Gantenerumab, MorphoSys, Pharmaceutical Industry, Pharmaceuticals, Phase III MARIANNE Study (Breast Cancer), Pre-Dementia (MCI), Prodromal Alzheimer's Disease, RG1577, Roche, Scarlet RoAD Study
|
Leave a comment
Eleven Genomics Medicine Centres Planned for England (BBC News / Department of Health / NHS England)
Summary The NHS has announced further steps in a genetics project, which will involve 11 Genomics Medicine Centres being created in English hospitals to gather DNA information. The aim is to support the 100,000 Genomes Project in research towards the … Continue reading →
Posted in Acute Hospitals, BBC News, Commissioning, Department of Health, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Integrated Care, National, NHS, NHS England, Person-Centred Care, Personalisation, Pharmacological Treatments, Quick Insights, Standards, UK, Universal Interest
|
Tagged 100000 Genome Project: NHS Genomic Medicine Centres, 100000 Genomes Project, Academic Health Science Networks (AHSNs), Advanced Therapies Facility (QEH), Advanced Therapies Facility: Birmingham NIHR / Wellcome Trust Clinical Research Facility (CRF), BBC Health News, BBC Wales News, Birmingham, Birmingham (UK), Birmingham and the Black Country (Dudley Sandwell Walsall and Wolverhampton), Birmingham CDRC, Birmingham Centre for Clinical Haematology, Birmingham Centre for Clinical Trials (BCCT), Birmingham Children’s Hospital, Birmingham City Council, Birmingham City Deal, Birmingham Experimental Arthritis Treatment Centre for Rheumatoid Arthritis (BEAT-RA), Birmingham Health Partners, Birmingham MRC Centre for Immune Regulation, Birmingham NIHR Liver Biomedical Research Unit (BRU), Cambridge, Cambridge University Hospitals NHS Foundation Trust: Genomics Medicines Centre, Cancer Research UK Centre, Cancer Research UK's Stratified Medicine Programme, Cardiff University’s MRC Centre for Neuropsychiatric Genetics and Genomics (MRC CNGG), Central Manchester University Hospitals NHS Foundation Trust: Genomics Medicines Centre, Centre for Clinical Haematology (CCH), Centre for Endocrinology Diabetes and Metabolism (CEDAM), Centre for Obesity Research, Centre for Translational Inflammation (CTIR), Centre for Translational Inflammation Research (QEH), Chronic Disease Resource Centre (CDRC), City of Sandwell and West Birmingham NHS Foundation Trust, Clinical Research Facility (QEH), Decoding Inherited Disorders, Dementia Research, DNA Extraction, Dudley Group of Hospitals, East of England, East of England NHS GMC: Cambridge University Hospitals NHS Foundation Trust, Exeter, Experimental Cancer Medicine Centre (ECMC), Genetic Disorders and Genomics, Genetic Profiling, Genetic Research, Genetic Susceptibility Loci, Genetic Triggers, Genetic Variants, Genetics of Alzheimer's Disease, Genomic Computing, Genomic Medicine, Genomic Medicine Centres, Genomic Medicine Centres (GMCs), Genomic Technologies, Genomics, Genomics England, Genomics in the NHS, Genomics Medicine Centres, Genomics-Based Medicine, Genotyping, George Freeman: Former Life Sciences Minister, Great Ormond Street Hospital NHS Foundation Trust: Genomics Medicines Centre, Greater Manchester, Greater Manchester NHS GMC: Central Manchester University Hospitals NHS Foundation Trust, Guy's and St Thomas' NHS Foundation Trust: Genomics Medicines Centre London, Health Research Bus (HRB), Health Research Trauma Management Healthcare Technology Co-operative (NIHR Trauma Management HTC), Henry Wellcome Building for Nuclear Magnetic Resonance Facility (HWB-NMR), Herceptin, Human Biomaterials Resource Centre (HBRC), Illumina, Imperial College Health Partners NHS GMC: Imperial College Healthcare NHS Trust, Imperial College Healthcare NHS Trust: Genomics Medicines Centre, Inflammation Research Facility (IRF): NIHR / Wellcome Trust Clinical Research Facility, Innovation, Innovation and Improvement, Innovation in Bioinformatics, Innovation in Biotechnology, Innovation in Genetics, Institute for Translational Medicine in Birmingham, Institute of Translational Medicine (ITM), Institute of Translational Medicine: University of Birmingham, Liverpool Women's NHS Foundation Trust: Genomics Medicines Centre, London, Medical Director of NHS England: Professor Sir Bruce Keogh, Microarrays, MRC ARUK Centre for Healthy Ageing, MRC Centre for Neuropsychiatric Genetics and Genomics (MRC CNGG), Multidisciplinary Assessment of Technology Centre for Healthcare (MATCH), National Institute for Health Research (NIHR), National Institute for Health Research Surgical Reconstruction and Microbiology Research Centre (NIHR SRMRC), Networks, Networks and Alliances, Newcastle upon Tyne Hospitals NHS Foundation Trust: Genomics Medicines Centre, Next-Generation Sequencing (NGS), NHS Five Year Forward View, NHS Five Year Forward View (5YFV), NHS Genomic Medicine Centres, NHS Genomic Medicine Centres Prospectus, NHS Genomics Medicine Centres, NHS Workforce, NIHR / Wellcome Trust Birmingham Clinical Research Facility (WTCRF), NIHR Clinical Research Facility, NIHR Collaborations for Leadership in Applied Health Research and Care for Birmingham and the Black Country (NIHR CLAHRC-BBC), NIHR Horizon Scanning Centre, NIHR Translational Research Partnerships (TRPs), North East, North East and North Cumbria NHS GMC: Newcastle upon Tyne Hospitals NHS Foundation Trust, North West Coast NHS GMC: Liverpool Women’s NHS Foundation Trust, Oxford, Oxford NHS GMC: Oxford University Hospitals Foundation Trust, Oxford University Hospitals Foundation Trust: Genomics Medicines Centre, Partnership, Partnership and Collaboration, Partnership Working, Personalised Medicine, Pharmaceutical Industry, Professor David Adams: Dean of Medicine at University of Birmingham Medical School, Professor Mark Caulfield: Chief Scientist at Genomics England, Professor Sir Bruce Keogh, Professor Sue Hill: Chief Scientific Officer for England, QMM: the Student Magazine of the University of Birmingham College of Medical and Dental Sciences, Queen Elizabeth Hospital, Research and Development, Research and Innovation, Research Commitment, Research Consortia, Research Culture, Research Into Aging, Research Networks, Researcher Access to Data, Resources for Researchers, Royal Devon and Exeter NHS Foundation Trust: Genomics Medicines Centre, Shape of Training Report, Shape Of Training Review, Sir John Chisholm: Executive Chair of Genomics England, South London NHS GMC: Guy’s and St Thomas’ NHS Foundation Trust, South West Peninsula, South West Peninsula NHS GMC: Royal Devon and Exeter NHS Foundation Trust, Southampton, Stem Cell Translational Medicine, STXBP1, Targeted Therapies, Translational Research, UK Genomes Project: Genomics England, UK Research and Life Science Sector, University College London Partners NHS GMC: Great Ormond Street Hospital NHS Foundation Trust, University Hospital Southampton NHS Foundation Trust: Genomics Medicines Centre, University Hospitals Birmingham NHS Foundation Trust, University Hospitals Birmingham NHS Foundation Trust: Genomics Medicines Centre, University Hospitals Birmingham: Cancer Clinical Specialties, University of Birmingham, University of Birmingham Medical School, Wales Infants and Children’s Genome Service (Wings), Wellcome Trust Clinical Research Facility, Welsh Government's Genomics for Precision Medicine Strategy (2017), Wessex NHS GMC: University Hospital Southampton NHS Foundation Trust, West Midlands, West Midlands Academic Health Network, West Midlands NHS GMC: University Hospitals Birmingham NHS Foundation Trust, West Midlands RDS: NIHR Research Design Service (RDS), Whole Genome Sequencing
|
Leave a comment
